AGS 16M18Alternative Names: AGS-16M18
Latest Information Update: 04 Jun 2010
At a glance
- Originator Agensys
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Surface antigen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Cancer
Most Recent Events
- 02 Feb 2010 Phase-I development is ongoing in USA and Canada